This free case-based activity includes a crowd-sourced discussion of a 72-year-old Caucasian male, who is a former smoker with a history of hypertension, diabetes, and BPH. He has NSCLC adenocarcinoma histology and is positive for the KRAS mutation G12C.
Originally posted on a forum in the ASCO Connection, users now have the opportunity to claim CME, completion, or participation certificates for completing this activity.
- Evaluate the data for immune checkpoint inhibitors as second line therapy in patients with advanced NSCLC
- Discuss the differences in efficacy based on PD-L1 status and smoking history
- Analyze the different antibodies and cut points being explored and how this applies to current practice
Medical Knowledge (ACGME, AAPA)
Health Promotion, Health Protection, Disease Prevention, and Treatment (ONS)